BBIO Stocktwits, News and Mentions. Forecasting BridgeBio Pharma, Inc. Sentiments







6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…

BBIO Stock News and Mentions of BridgeBio Pharma, Inc. Stocktwits

Updated: March 29, 2024 (09:56)

Sector: Healthcare

Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.

We meticulously analyze the sentiment trend in each article for the last 60 days where BridgeBio Pharma Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of BridgeBio Pharma, Inc. (BBIO).

You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the BridgeBio Pharma stocks.


Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles

News and Mentions of BridgeBio Pharma, Inc. (BBIO)

March 20, 2024 (11:30) / "GlobeNewswire" (by BridgeBio Pharma)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )

PALO ALTO, Calif., March 20, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 16, 2024, the compensation committee of ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (11:30) / "Benzinga" (by Globe Newswire)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BridgeBio Pharma ( NASDAQ:BBIO )

PALO ALTO, Calif., March 20, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
In Article Trend: Somewhat-Bullish
March 6, 2024 (04:53) / "GlobeNewswire" (by Inc.)

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

PALO ALTO, Calif., March 05, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 ...
In Article Trend: Neutral
March 5, 2024 (13:00) / "Benzinga" (by Globe Newswire)

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO )

BOSTON and PLEASANTON, Calif., March 05, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc AKTX, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc.
In Article Trend: Neutral
March 5, 2024 (13:00) / "Benzinga" (by Globe Newswire)

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO )

BOSTON and PLEASANTON, Calif., March 05, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc AKTX, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc.
In Article Trend: Neutral
March 4, 2024 (21:17) / "Benzinga" (by Globe Newswire)

BridgeBio Pharma Announces Proposed Public Offering of Common Stock - BridgeBio Pharma ( NASDAQ:BBIO )

PALO ALTO, Calif., March 04, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. BBIO ( "BridgeBio" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common ...
In Article Trend: Neutral
March 4, 2024 (21:17) / "GlobeNewswire" (by BridgeBio Pharma)

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

PALO ALTO, Calif., March 04, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares ...
In Article Trend: Neutral
March 4, 2024 (17:31) / "Benzinga" (by Vandana Singh)

What's Going On With BridgeBio Pharma Stock On Monday? - BridgeBio Pharma ( NASDAQ:BBIO )

Monday, BridgeBio Pharma Inc BBIO and Bayer AG BAYRY BAYZF announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million, including upfront and near-term milestone payments and ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (07:30) / "GlobeNewswire" (by BridgeBio Pharma)

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy ( ATTR-CM ) in Europe ...
In Article Trend: Somewhat-Bullish
February 22, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)

BridgeBio Pharma ( BBIO ) Reports Q4 Loss, Lags Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.05% and 74.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
February 15, 2024 (15:23) / "Benzinga" (by Avi Kapoor)

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday - Albemarle ( NYSE:ALB ) , American Well ( NYSE:AMWL )

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. Shares of Reliance Steel & Aluminum Co. RS rose sharply in today's session after the company reported fourth-quarter earnings above estimates and issued above-consensus first-quarter FY24 adjusted ...
In Article Trend: Bullish
February 15, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)

Analysts Estimate BridgeBio Pharma ( BBIO ) to Report a Decline in Earnings: What to Look Out for

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
February 14, 2024 (03:07) / "PR Newswire" (by Invitae Corporation)

Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process

Invitae Files for Voluntary Chapter 11 Protection. Pursues Sale Process PR ...
In Article Trend: Somewhat-Bullish
February 7, 2024 (12:34) / "GlobeNewswire" (by BridgeBio Pharma)

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan ...
In Article Trend: Somewhat-Bullish
February 2, 2024 (12:00) / "GlobeNewswire" (by Inc.)

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy ( ATTR-CM ) Including No Mortality Reported in the Trial at 30 Months

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial ...
In Article Trend: Neutral



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.